MBBS, FRCA, FRCP, FJFICM
Charlie is a Senior Intensive Care Specilaist at University Hospital Geelong, and the President of the College of Intensive Care Medicine
He undertook medical training at St Bartholomew’s hospital in London. After training as a physician he converted to anaesthesia and finally settled on becoming an intensive care specialist. After working in Hong Kong he came to Australia, initially working as Director of Intensive Care at the Repatriation Hospital in Melbourne. In 1991 he became Director of Intensive Care in Geelong. He has had extensive invovlement with the College of Intensive Care Medicine, serving as an Examiner, and an Executive Member since 2003. In 2008 he stepped down as Director of ICU at UHG to concentrate on his diverse medical interests.
Charlies careers include;
- Former President of the College of Intensive Care Medicine
- Regional clinical lead for the Respecting Patient Choices program
- Originator of the ‘MyValues’ approach to advance care planning
- Former Director ICU, Bawon Health
Charlie has published a number of papers and books on medicine and was featured on the ABC in the film ‘In the End’, and 'Insight'.
Respecting Patient Choices
Latest news:
-
Thursday, August 26, 2021 - 01:57
JAMA BaSICS rate: Slower vs faster fluid challenge in critically ill patients not significantly reduce 90-day mortality. In addition there was a lower use of vasopressors on day 3 in the slower infusion rate group. Adds to SPLIT and SMART trials.
Monday, August 23, 2021 - 13:54NEJM Convalescent plasma RCT for high-risk patients present to ED within 7 days after the onset of symptoms = no difference disease progression
Monday, August 23, 2021 - 12:27NEJM VITT review 237 suspected from 24 million Oxford-Astra Zeneca doses, incidence at least 1:100,000 >50 years, 1:50,000 <50 years, occurs 5-30 days after first dose. Extensive thrombotic sites, cerebral venous thrombosis dominant. Low platelets, increased D-dimer, reduced fibrinogen associated worse outcomes. Overall case fatality rate 23%, highest in patients with both ICH and platelet count below 30,000. No therapeutic options proven effective, although IVIG, corticosteroids, plasma exchange, and non-heparin anticoagulation are used.
Sunday, August 22, 2021 - 19:03JC DOREMI RCT reports no difference in composite primary outcome with milrinone vs dobutamine for cardiogenic shock (49% M vs 54% D, RR, 0.90; 95% CI, 0.69 to 1.19; P=0.47). No difference in secondary outcomes. It was powered to detect a large effect.
Sunday, August 22, 2021 - 11:21REMAP-CAP, ACTIV-4a, and ATTACC harmonised multiplatform, randomized trial 2244 non-ICU patients with COVID- for every 1000 patients, therapeutic anticoagulation vs thromboprophylaxis expected to result in 40 additional patients surviving to hospital discharge without organ support, and 7 major bleeds.